Datapoint: Entresto Scores Expanded Heart Failure Label

The FDA last week approved a label expansion for Novartis’s Entresto, boosting its potential patient pool by millions of lives. The blockbuster drug is now approved for both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in patients whose left ventricular ejection fraction (LVEF) is below normal levels. For the treatment of chronic heart failure, Entresto currently holds preferred formulary placement for 50% of all covered lives, growing to 78% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/17/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 2

Datapoint: Amgen Asks Supreme Court to Hear Repatha Case

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 1

Datapoint: United to Join Massachusetts Duals Demo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 30

Datapoint: Oscar, Emory to Offer New Health Plan in Georgia

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today